Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.2100
- TODAY'S CHANGE (%)-0.0900 (-2.7273%)
- Bid / Lots3.2100/ 2
- Ask / Lots3.2200/ 6
- Open / Previous Close3.3000 / 3.3000
- Day Range
- 52 Week Range
- Volume143,544
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 4831 | 3.32 |
| 09:36 ET | 2599 | 3.26 |
| 09:39 ET | 1858 | 3.245 |
| 09:41 ET | 1657 | 3.23 |
| 09:43 ET | 248 | 3.2354 |
| 09:45 ET | 1697 | 3.23 |
| 09:50 ET | 100 | 3.26 |
| 09:52 ET | 1500 | 3.2349 |
| 09:54 ET | 100 | 3.235 |
| 09:56 ET | 400 | 3.22 |
| 09:59 ET | 700 | 3.2194 |
| 10:01 ET | 200 | 3.22 |
| 10:03 ET | 610 | 3.22 |
| 10:06 ET | 1381 | 3.23 |
| 10:10 ET | 200 | 3.245 |
| 10:12 ET | 115 | 3.245 |
| 10:14 ET | 729 | 3.22 |
| 10:15 ET | 526 | 3.21 |
| 10:26 ET | 100 | 3.21 |
| 10:28 ET | 1593 | 3.2093 |
| 10:30 ET | 506 | 3.205 |
| 10:35 ET | 2797 | 3.21 |
| 10:37 ET | 100 | 3.225 |
| 10:42 ET | 300 | 3.24 |
| 10:44 ET | 200 | 3.24 |
| 10:50 ET | 700 | 3.23 |
| 10:51 ET | 100 | 3.225 |
| 10:53 ET | 1020 | 3.22 |
| 10:55 ET | 324 | 3.215 |
| 10:57 ET | 37987 | 3.24 |
| 11:06 ET | 1510 | 3.22 |
| 11:08 ET | 1000 | 3.21 |
| 11:09 ET | 200 | 3.2 |
| 11:11 ET | 800 | 3.2 |
| 11:15 ET | 338 | 3.205 |
| 11:18 ET | 12158 | 3.2 |
| 11:20 ET | 100 | 3.19 |
| 11:22 ET | 100 | 3.19 |
| 11:24 ET | 100 | 3.19 |
| 11:26 ET | 2038 | 3.19 |
| 11:29 ET | 100 | 3.19 |
| 11:31 ET | 100 | 3.2 |
| 11:33 ET | 26287 | 3.225 |
| 11:36 ET | 9774 | 3.215 |
| 11:38 ET | 7396 | 3.2133 |
| 11:42 ET | 100 | 3.2 |
| 11:44 ET | 100 | 3.2 |
| 11:45 ET | 1000 | 3.22 |
| 11:47 ET | 1200 | 3.21 |
| 11:51 ET | 360 | 3.21 |
| 11:54 ET | 611 | 3.21 |
May 15, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones*DJ Kodiak Sciences 1Q Loss/Shr 82c >KOD, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy, from 7:32PM ET on Monday May 13, 2024 by Dow Jones
7:32PM ET on Monday May 13, 2024 by Dow Jones
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 173.4M | -0.7x | --- |
Achieve Life Sciences Inc | 171.3M | -3.8x | --- |
Greenwich Lifesciences Inc | 180.0M | -19.2x | --- |
Outlook Therapeutics Inc | 181.3M | -2.0x | --- |
Cardiff Oncology Inc | 162.4M | -4.0x | --- |
Gossamer Bio Inc | 157.0M | -0.6x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $173.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.43 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
